Innate lymphoid cells – the European quest for innovative cancer prognosis and immunotherapy

COST Action CA24117

ILCquest is a pan-European COST Action dedicated to advancing the understanding of innate lymphoid cells (ILCs) and their role in cancer prognosis, immune regulation, and immunotherapy.

By bringing together clinicians, immunologists, cancer biologists, and data scientists, the Action aims to bridge fundamental research and clinical application, fostering innovative strategies for cancer diagnosis, patient stratification, and treatment.

Objectives

• Strengthening European collaboration on ILC research

• Attaining uniformed methodology and terminology across laboratories

• Promoting translation of ILC biology into clinical oncology and immunotherapy

• Supporting early-career researchers through training, networking, and mobility

Latest News

Open Call for ILCquest Grant Applications for 2027!

Open Call for ILCquest Grant Applications for 2027! Are you an ILCquest member looking to expand your research, build international collaborations or present your scientific work? We invite you to...

Webinar announcement: Dr. Amara Moussa, 26 October 2026

Webinar announcement: Dr. Amara Moussa, 26 October 2026 ILCquest is pleased to invite you to an upcoming webinar featuring Dr. Amara Moussa, PhD Candidate in Clinical and Experimental Immunology...

ILCquest Management Committee Meeting held in Madrid, Spain

ILCquest Management Committee Meeting held in Madrid, Spain On 17 September 2026, our COST Action held its Management Committee Meeting at the Faculty of Medicine, Universidad Complutense de Madrid...